Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrodinger Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Schrodinger (SDGR – Research Report), Compass Therap...

Market Cap	$1.40B	P/E Ratio	N/A
52W High	$28.47	52W Low	$15.99
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-21.9%	52W Position	16.5%
Overall Score	42	Value Score	55
Quality Score	28	Technical Score	45

EPS Current Est	$-1.91	EPS Next Est	$-0.77
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SDGR	$18.05	-0.44%	946.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SDGR	$18.05	-0.4%	946.41K
3
4
5
6

SDGR

SDGR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Schrodinger Inc. Data in Excel

Get Schrodinger Inc. Data in Excel